Table 1.
Clinical Characteristics of patients with COVID-19 (N = 249).
|
Clinical characteristics |
Normal range | Mean ± SD | Median (IQR)/n |
|---|---|---|---|
| White blood cell count, × 109/L | 3.5–4.5 | 7.7 ± 4.3 | 7.4(4.9–9.3)/247 |
| Neutrophils count, × 109/L | 1.8–6.3 | 69.09 ± 15.54 | 6.9(5.9–8.3)/247 |
| Lymphocytes count, × 109/L | 1.1–3.2 | 1.60 ± 1.37 | 2.1(1.2–3.1)/247 |
| Platelet, × 109/L | 125–350 | 191.29 ± 92.24 | 181(137–231)/247 |
| Hb, g/L | 11.5–15.0 | 12.40 ± 2.34 | 12.72(11.14–4.65)/247 |
| PT, s | 9–14 | 14.46 ± 6.40 | 13(12–14.28)/240 |
| aPTT, s | 20–40 | 34.34 ± 14.01 | 31.2(27.9–35.05)/93 |
| Serum sodium, mmol/L | 135–145 | 138.49 ± 5.57 | 139(136–142)/246 |
| Serum potassium, mmol/L | 3.5–4.5 | 4.25 ± 0.74 | 4.2(3.8–4.2)/246 |
| Serum chloride, mmol/L | 95–105 | 95.77 ± 10.35 | 97(94–99)/244 |
| AST, U/L | 8–40 | 58.26 ± 78.92 | 35.9(24.1–59.8)/244 |
| ALT, U/L | 5–35 | 203.53 ± 141.59 | 36(24.8–62.3)/246 |
| LDH, U/L | 109–245 | 729.20 ± 621.44 | 513.3(425.7–817)/46 |
| Direct bilirubin, mmol/L | 0.1–0.3 | 0.65 ± 2.10 | 0.3(0.22–0.42)/246 |
| Indirect bilirubin, mmol/L | 0.2–0.8 | 0.54 ± 1.59 | 0.26(0.18–0.39)/245 |
| TBIL, mmol/L | 3.4–20.5 | 1.19 ± 3.63 | 0.56(0.4–0.8)/246 |
| CRP, mg/L | 0–5 | 56.73 ± 89.87 | 10.15(2.46–79.25)/145 |
| D-dimer, ng/mL | <250 | 723.69 ± 702.43 | 623(333–908)/55 |
| CPK-MB | 0–25 | 38.72 ± 39.35 | 27.2(18.55–39.05)/85 |
| Procal, ng/mL | <.004 | 8.50 ± 16.97 | 0.19(.04–5.4)/55 |
| PaO2, mmHg | 75–100 | 88.25 ± 14.74 | 98(84–92)/249 |
| SpO2, % | 95–100 | 94.40 ± 6.62 | 96(94–98)/248 |
LDL low-density lipoprotein; HDL high-density lipoprotein; TBIL total bilirubin; ALT alanine aminotransferase; AST aspartate transaminase; CK-MB creatinine kinase muscle and brain; APTT activated partial thromboplastin time; PT prothrombin time; CRP C –reactive protein; Proca procalcitonin; Hb hemoglobin.